Gene-editing reverses vision loss in mice
Researchers in China successfully restored the vision of mice with retinitis pigmentosa, a major cause of blindness in humans. The research, published Friday in the Journal of Experimental Medicine, describes a new form of CRISPR-based genome editing which has the potential to correct a variety of disease-causing genetic mutations. Read More
HIV potentially cured by transplanting umbilical cord stem cells in mixed race woman
Transplanting stem cells from umbilical cord blood has potentially cured a mixed-race woman of HIV and freed her from taking antiviral medication, according to a case report published in Cell. Read More
Simpler, cheaper screening method developed to democratize COVID-19 drug discovery
An alternative method for finding single-chain antibodies has yielded COVID-19 drug candidates that may be effective against variants of concern. Read More
Enzyme-activated drug candidate points to new way to treat liver cancer
Small molecules that are activated by an enzyme produced by some tumors could improve the treatment of liver cancer, a study run by scientists at the National Institutes of Health (NIH) and Massachusetts General Hospital suggests. Read More
GHIT Fund provides $1.9M for malaria drug development
The Global Health Innovative Technology (GHIT) Fund on Monday announced approximately $1.9 million (260 million yen) in funding for the research and development of a new malaria drug. Read More
A new immune pathway sheds light on ALS
A study indicates that inflammatory proteins involved in the innate immune system cause neuron damage and play a role in neurodegenerative diseases. Read More
Therapeutic target may aid in glaucoma treatment
Indiana University School of Medicine researchers have identified a new therapeutic target that could lead to more effective glaucoma treatment. The research, published recently in Communications Biology, found that restoring mitochondrial homeostasis in diseased neurons can protect optic nerve cells from being damaged. Read More
Pfizer to acquire Seagen for $43 billion
Pfizer will acquire Seagen, a firm specializing in the discovery and development of treatments for cancer, the firms announced on Monday. Read More
Exclusion of racial groups from cancer genomics research has negative impacts
The lack of genomic research for people with African ancestry is hampering efforts to reduce health disparities for people with cancer, according to recent research. Read More
Correlation of enzyme to survival reveals potential target for metastatic solid tumors
The enzyme lysyl hydroxylase 1 (LH1) promotes the migration and metastasis of solid tumor cells and is associated with shorter survival, according to a recent study published in Molecular Cancer. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
